Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

CGF 166

Next Previous
X
Search
Drug Profile

CGF 166

Alternative Names: CGF166; Hearing loss gene therapy

Latest Information Update: 26 Mar 2020

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Baylor College of Medicine
  • Developer GenVec; Novartis
  • Class Gene therapies
  • Mechanism of Action Gene transference
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Phase I/II Hearing loss

Most Recent Events

  • 09 Dec 2019 Novartis completes a phaseI/II trial in Hearing loss in USA (NCT02132130)
  • 03 Aug 2017 GenVec plans a phase IIb trial for Hearing loss (GenVec pipeline, August 2017)
  • 16 Jun 2017 GenVec has been acquired by Intrexon Corporation

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top